MADRID, November 7, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM) has announced today a licensingagreement with Boryung Pharm to commercialize the marine-derived anticancer drug ZepsyreŽ (lurbinectedin), if approved, in South Korea. Under the terms of the agreement, PharmaMar receives a non-disclosed upfront payment
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
ZepsyreŽ is currently in late-stage clinical development for platinum-resistant ovarian cancer and for small-cell lung cancer. After results obtained in clinical trials about BRCA 2-associated metastatic breast cancer and endometrial cancer, PharmaMar also plans to initiate a pivotal phase III study in each of those indications.
According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, "This is our second strategic agreement with Boryung Pharm and we are very pleased with our business partner. This new agreement will allow ZepsyreŽ to reach the Korean market, if approved, in the hands of one of the leading companies in the field of oncology in this country."
Boryung Pharm Chief Executive Officer, Mr. Tae-Hong Choi said, "We are very pleased to have our second licensing deal with PharmarMar. This licensing deal will strengthen our existing strong relationship with PharmaMar and demonstrate our high confidence in PharmaMar`s development pipeline." He added: "ZepsyreŽ may provide new therapies in various types of solid tumors, including a platinum-resistant ovarian cancer, BRCA 2-associated metastatic breast cancer and small-cell lung cancer. We look forward to making these new therapies available in South Korea, if approved."
Contact: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914-44-45-00)
Subscribe to our Free Newsletters!
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...View All